Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Income towards Parent Company: 2014-2024

Historic Income towards Parent Company for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to -$570.6 million.

  • Ultragenyx Pharmaceutical's Income towards Parent Company fell 35.12% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$581.2 million, marking a year-over-year decrease of 3.97%. This contributed to the annual value of -$570.6 million for FY2024, which is 5.95% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Income towards Parent Company stood at -$570.6 million for FY2024, which was up 5.95% from -$606.6 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's 5-year Income towards Parent Company high stood at -$190.7 million for FY2020, and its period low was -$710.7 million during FY2022.
  • In the last 3 years, Ultragenyx Pharmaceutical's Income towards Parent Company had a median value of -$606.6 million in 2023 and averaged -$629.3 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 52.69% in 2020, then crashed by 139.36% in 2021.
  • Ultragenyx Pharmaceutical's Income towards Parent Company (Yearly) stood at -$190.7 million in 2020, then tumbled by 139.36% to -$456.4 million in 2021, then plummeted by 55.74% to -$710.7 million in 2022, then increased by 14.65% to -$606.6 million in 2023, then climbed by 5.95% to -$570.6 million in 2024.